Skip to main content
. Author manuscript; available in PMC: 2016 Sep 29.
Published in final edited form as: Lancet Oncol. 2011 Oct 25;12(13):1222–1228. doi: 10.1016/S1470-2045(11)70265-0

Table 2.

Treatment-related grade 3 or 4 adverse events in ≥ 5% of Patients

Preferred Term
n (%)
Initial Dose 85mg
(n=28)
Initial Dose 110 mg
(n=23)
Total
(n=51)
Thrombocytopenia 7 (25.0) 4 (17.4) 11 (21.6)
Fatigue 3 (10.7) 5 (21.7) 8 (15.7)
Neutropenia 3 (10.7) 4 (17.4) 7 (13.7)
Pneumonia 2 (7.1) 4 (17.4) 6 (11.8)
Anemia 4 (14.3) 1 (4.3) 5 (9.8)
Pericardial effusion 1 (3.6) 2 (8.7) 3 (5.9)
Abnormal liver function test 1 (3.6) 2 (8.7) 3 (5.9)